KEY POINTS
-
Eli Lilly broke ground Sept. 21 on a $6.5 billion active pharmaceutical ingredient manufacturing site in Houston.
-
The project is expected to support approximately 4,000 construction jobs during development and more than 600 permanent, high-wage positions once operational.
-
Lilly said the facility will use AI, machine learning and digital automation in production.
Eli Lilly and Company broke ground on a $6.5 billion pharmaceutical manufacturing facility in Houston, marking the company’s fifth U.S. site planned to produce active pharmaceutical ingredients, or APIs. The announcement was made by Lilly on Sept. 21, 2026.
A Major Investment in Houston
The Houston project is part of Lilly’s broader effort to expand domestic medicine production, which the company said has grown to more than $50 billion in planned U.S. manufacturing investment since 2020. Lilly outlined that expansion in a February 2025 announcement, saying the build-out is intended to strengthen supply chains and add manufacturing and construction employment.
The Houston plant will manufacture Foundayo, Lilly’s oral GLP-1 medicine, along with other medicines and advanced therapies. Lilly says the site will use established chemical-production methods that can be scaled in an industrial facility.
Construction and Workforce Impacts
Lilly expects the Houston development to create approximately 4,000 construction jobs as the facility is built and brought online. Once operating, the site is expected to employ more than 600 people in roles including engineering, science, operations and laboratory work.
The project represents a large-scale potential opportunity for contractors, suppliers and other firms serving the manufacturing sector, including:
-
Pharmaceutical process manufacturing
-
Advanced production systems
-
Supporting infrastructure
Lilly’s announcement did not identify a construction manager, general contractor or project delivery schedule.
A rendering of the Eli Lilly and Company $6.5 billion pharmaceutical manufacturing facility in Houston. Image: Eli Lilly and Company
Construction labor remains challenging as firms compete for skilled workers amidst increasing wage pressure. Lilly addressed the labor issue, saying it is investing in the regional talent pipeline through:
-
A planned $12.5 million relationship with Greater Houston's San Jacinto College focused on training pathways and expanded equipment and facility capacity
-
Preparation for technicians, operators, maintenance professionals and other manufacturing workers
-
A separate $2.5 million donation to the San Jacinto College Foundation for eligible student scholarships
Digital Systems Will Be Embedded in Production
Lilly said digital automation will be integrated throughout the Houston site to support reliable production of safe, high-quality medicines. The planned technology stack includes AI, machine learning, connected digital systems and advanced analytics.
In Houston, Lilly's technology will be paired with advanced chemical synthesis and production of next-generation therapies, it said, thus creating requirements that extend beyond conventional industrial building systems.
The Houston facility is one of 10 U.S. manufacturing sites Lilly announced since 2020. Five are planned for API production, four for injectable medicines and devices, and one for genetic medicines, according to the company’s project announcement.
About ConstructConnect
At ConstructConnect, our software solutions provide the information construction professionals need to start every project on a solid foundation. For more than 100 years, our insights and market intelligence have empowered commercial firms, manufacturers, trade contractors, and architects to make data-driven decisions and maximize productivity.
ConstructConnect is a business unit of Roper Technologies (Nasdaq: ROP), part of the Nasdaq 100, S&P 500, and Fortune 1000.
For more information, visit constructconnect.com
.jpg)
